Interviews - Page 5 of 7

Theranostics in nuclear medicine is a modern, mainstream approach that unites cancer diagnosis and treatment into a single, integrated system. It not only enables precise identification of tumors and their metastases but also allows targeted radionuclide therapy. Today, these methods are increasingly being included in international treatment protocols and offer patients a real chance to extend their lives and improve quality of life.

We live in a world where data means a lot. But what if some of that data only creates the illusion of control, while actually making it harder to make decisions? This uncomfortable truth was explored in depth by Irina McLean, Health and Social Care Research Coordinator at NHS Research Scotland.

Doctor Paul Hercock: “90% of medtech startups never make it to market.” How the absence of a go‑to‑market plan kills promising technologies. For every device that successfully reaches the market, there are about ten that are abandoned long before launch. Even among those that clear regulatory hurdles, a significant number fail to achieve commercial success. The reason often isn’t the quality of the solutions or a lack of expertise, but the absence of a clear go‑to‑market strategy and consideration of all stakeholders in the healthcare system. Clinicians involved in development often know what the market needs, but don’t know how…